Dynavax DVAX Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Dynavax DVAX

DVAX 10.24

+1.8%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: kenhott	3/18/2008 10:54:46 AM
	of 184

Just drive-by thinking here (I googled wegener since I was curious). I will assume that the patient didn't get classified because he/she had the mild form of the disease. So either (1) the patient progressed while "on drug" or (2) the drug had initiated the disease w/progression. I understand why someone may think that 2 doses over a month may not give a problem. But the drug is an immune stimulator so (2) is bad but is (1) much much better? This drug is a vaccine and not one that is uniquely capable in HBV. I don't think one can expect much support for prescreening for autoimmune problems unless there is a niche that can only be serve by this drug. The easy out would be they misdiagnosed the problem. Ok, time to shut up.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next